Myeloid-Derived Suppressor Cells in Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 1464
Special Issue Editor
Special Issue Information
Dear Colleagues,
During their development and progression, tumors acquire specific properties that enable them to evade immune responses, creating conditions that suppress the antitumor immune response. Over the past decade, the generation and expansion of myeloid-derived suppressor cells (MDSCs) have emerged as a critical mechanism for cancer-induced immunosuppression. MDSCs are a heterogeneous group of immature myeloid cells that induce potent immunosuppression by producing various immune-inhibitory cytokines, enzymes, and chemically reactive molecules containing oxygen and nitrogen. Extensive clinical and experimental studies have shown that MDSC levels correlate with tumor burden, stage, and short-term survival. Consequently, MDSCs are now considered major challenges in cancer immunotherapies, and targeting them could be a highly valuable strategy to enhance the effectiveness of chemotherapeutic and immunotherapeutic approaches.
Experimental tumor models have contributed significantly to a better understanding of the underlying mechanisms involved in the development, homing, and functionality of MDSCs in tumors. They have also been instrumental in testing anti-MDSC therapies in vivo. However, the precise role of tumor cells, host cells, and microbiota in generating and expanding these cells remains elusive.
Furthermore, information obtained from experimental tumors cannot be directly applied to patients with cancer because of the substantial heterogeneity of MDSCs across different cancer types. Additionally, the lack of specific biomarkers and a straightforward separation/characterization technique for human MDSCs has resulted in limited knowledge about tumor-infiltrating MDSCs in human cancers and their roles in tumor progression and metastasis.
This Special Issue, entitled "Myeloid-Derived Suppressor Cells in Cancer" aims to consider papers for publication that address the aforementioned challenges related to MDSCs in different cancers, as well as those exploring the biology of MDSCs and novel modalities that target these cells in cancer.
Dr. Manuchehr Abedi-Valugerdi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- tumor
- myeloid-derived suppressor cells (MDSCs)
- immunosuppression
- immune escape
- myelopoiesis
- G-MDSCs
- M-MDSCs
- biomarkers
- tumor models
- extramedullary hematopoiesis
